Business Description
Genovis AB
ISIN : SE0002485979
Total Employee Number:
36Compare
Compare
Traded in other countries / regions
GENO.Sweden5GV.Germany IPO Date
2005-12-30Description
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.15 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | 2.09 | |||||
Interest Coverage | 15.41 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.45 | |||||
Beneish M-Score | -1.67 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.8 | |||||
3-Year EBITDA Growth Rate | 41.7 | |||||
3-Year EPS without NRI Growth Rate | 2 | |||||
3-Year Book Growth Rate | 28.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.83 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 25.94 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.17 | |||||
9-Day RSI | 42.85 | |||||
14-Day RSI | 45.93 | |||||
3-1 Month Momentum % | 5.41 | |||||
6-1 Month Momentum % | 0.25 | |||||
12-1 Month Momentum % | -23.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.76 | |||||
Quick Ratio | 5.76 | |||||
Cash Ratio | 4.44 | |||||
Days Inventory | 302.61 | |||||
Days Sales Outstanding | 66.69 | |||||
Days Payable | 95.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | 0.27 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.42 | |||||
Operating Margin % | 14.78 | |||||
Net Margin % | 15.11 | |||||
EBITDA Margin % | 25.79 | |||||
FCF Margin % | 37.75 | |||||
OCF Margin % | 37.75 | |||||
ROE % | 7.54 | |||||
ROA % | 5.43 | |||||
ROIC % | 7.68 | |||||
3-Year ROIIC % | 7.61 | |||||
ROC (Joel Greenblatt) % | 19.81 | |||||
ROCE % | 5.69 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 63.73 | |||||
Forward PE Ratio | 49.3 | |||||
PE Ratio without NRI | 63.73 | |||||
Shiller PE Ratio | 73.01 | |||||
Price-to-Owner-Earnings | 44.16 | |||||
PEG Ratio | 1.54 | |||||
PS Ratio | 9.33 | |||||
PB Ratio | 4.19 | |||||
Price-to-Tangible-Book | 7.35 | |||||
Price-to-Free-Cash-Flow | 24.67 | |||||
Price-to-Operating-Cash-Flow | 24.67 | |||||
EV-to-EBIT | 59.88 | |||||
EV-to-EBITDA | 34.31 | |||||
EV-to-Revenue | 8.85 | |||||
EV-to-FCF | 23.44 | |||||
Price-to-GF-Value | 0.71 | |||||
Price-to-Projected-FCF | 1.91 | |||||
Price-to-Median-PS-Value | 0.53 | |||||
Price-to-Peter-Lynch-Fair-Value | 4.88 | |||||
Price-to-Graham-Number | 4.56 | |||||
| Price-to-Net-Current-Asset-Value | 15.42 | |||||
| Price-to-Net-Cash | 34.76 | |||||
Earnings Yield (Greenblatt) % | 1.67 | |||||
FCF Yield % | 3.97 | |||||
Forward Rate of Return (Yacktman) % | 16.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genovis AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 135.606 | ||
| EPS (TTM) (kr) | 0.3 | ||
| Beta | 0.8919 | ||
| 3-Year Sharpe Ratio | -0.32 | ||
| 3-Year Sortino Ratio | -0.44 | ||
| Volatility % | 28.89 | ||
| 14-Day RSI | 45.93 | ||
| 14-Day ATR (kr) | 0.972057 | ||
| 20-Day SMA (kr) | 19.3985 | ||
| 12-1 Month Momentum % | -23.26 | ||
| 52-Week Range (kr) | 15.64 - 28.15 | ||
| Shares Outstanding (Mil) | 67.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genovis AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genovis AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 98 days | ||
| Second quarter earnings results for 2026 | 2026-07-23 | 19.46 (+1.04%) | ||
| General meeting for 2026 | 2026-05-18 | 20.65 (-0.48%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 20.05 (+0.35%) | ||
| Annual report for 2025 | 2026-04-23 | 20.30 (+0.50%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 | 19.72 (-0.40%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 22.05 (+1.85%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 27.10 (+3.83%) | ||
| General meeting for 2025 | 2025-05-21 17:00 | 24.45 (-1.41%) | ||
| First quarter earnings results for 2025 | 2025-05-21 | 24.45 (-1.41%) |
Show
Entries
Genovis AB Frequently Asked Questions
What is Genovis AB(OSTO:GENO)'s stock price today?
The current price of OSTO:GENO is kr19.12. The 52 week high of OSTO:GENO is kr28.15 and 52 week low is kr15.64.
When is next earnings date of Genovis AB(OSTO:GENO)?
The next earnings date of Genovis AB(OSTO:GENO) is 2026-11-10.
Does Genovis AB(OSTO:GENO) pay dividends? If so, how much?
Genovis AB(OSTO:GENO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Genovis AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers